Valneva (NASDAQ:VALN) Stock Price Down 4.6% – Time to Sell?
by Amy Steele · The Cerbat GemValneva SE Sponsored ADR (NASDAQ:VALN – Get Free Report) dropped 4.6% on Tuesday . The stock traded as low as $8.07 and last traded at $8.3890. Approximately 29,606 shares were traded during trading, a decline of 51% from the average daily volume of 60,637 shares. The stock had previously closed at $8.79.
Wall Street Analysts Forecast Growth
Several research analysts recently issued reports on the stock. Guggenheim decreased their price target on shares of Valneva from $14.00 to $13.00 and set a “buy” rating for the company in a research note on Monday, September 8th. Wall Street Zen cut shares of Valneva from a “hold” rating to a “sell” rating in a report on Saturday, December 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Valneva in a research note on Wednesday, October 8th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $15.00.
Get Our Latest Analysis on Valneva
Valneva Price Performance
The firm’s fifty day simple moving average is $8.90 and its 200-day simple moving average is $8.63. The firm has a market capitalization of $719.45 million, a PE ratio of -5.82 and a beta of 1.83. The company has a quick ratio of 1.36, a current ratio of 1.78 and a debt-to-equity ratio of 0.72.
Valneva (NASDAQ:VALN – Get Free Report) last released its quarterly earnings data on Thursday, November 20th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.31). The business had revenue of $34.01 million during the quarter, compared to the consensus estimate of $48.85 million. Valneva had a negative net margin of 57.81% and a negative return on equity of 59.44%. On average, research analysts forecast that Valneva SE Sponsored ADR will post 0.13 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Valneva
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Marex Group plc purchased a new stake in shares of Valneva during the 2nd quarter valued at about $64,000. VSM Wealth Advisory LLC raised its holdings in shares of Valneva by 125.0% during the third quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock valued at $110,000 after purchasing an additional 5,000 shares during the last quarter. JPMorgan Chase & Co. bought a new position in Valneva during the third quarter valued at approximately $124,000. Finally, Frazier Life Sciences Management L.P. purchased a new stake in Valneva in the second quarter worth approximately $8,240,000. Institutional investors own 11.39% of the company’s stock.
About Valneva
Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.
Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.